Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-2,740
Closed -$559K 297
2022
Q2
$559K Sell
2,740
-808
-23% -$165K 0.14% 157
2022
Q1
$748K Sell
3,548
-1,663
-32% -$362K 0.16% 141
2021
Q4
$1.25M Sell
5,211
-2,313
-31% -$595K 0.25% 110
2021
Q3
$2.13M Buy
7,524
+5
+0.1% +$1.64K 0.47% 56
2021
Q2
$2.6M Buy
7,519
+1,845
+33% +$559K 0.62% 46
2021
Q1
$1.59M Sell
5,674
-709
-11% -$191K 0.55% 54
2020
Q4
$1.56M Buy
6,383
+782
+14% +$202K 0.54% 55
2020
Q3
$1.59M Sell
5,601
-56
-1% -$15.6K 0.66% 45
2020
Q2
$1.51M Sell
5,657
-142
-2% -$42.7K 0.67% 44
2020
Q1
$1.83M Sell
5,799
-518
-8% -$157K 0.93% 30
2019
Q4
$1.88M Sell
6,317
-1,145
-15% -$318K 0.76% 40
2019
Q3
$1.74M Buy
7,462
+416
+6% +$96.9K 0.73% 43
2019
Q2
$1.65K Buy
7,046
+1,057
+18% +$244K 0.7% 46
2019
Q1
$1.42K Sell
5,989
-253
-4% -$79.7K 0.61% 53
2018
Q4
$1.88K Buy
6,242
+95
+2% +$30.3K 0.89% 36
2018
Q3
$2.17M Sell
6,147
-63
-1% -$21.7K 0.87% 43
2018
Q2
$1.8M Buy
6,210
+99
+2% +$27.8K 0.77% 47
2018
Q1
$1.67M Buy
6,111
+3,788
+163% +$1.18M 0.71% 48
2017
Q4
$740K Buy
+2,323
New +$745K 0.3% 83

Other funds holding BIIB

Chicago Trust's BIIB Position: Q3 2022 in Review

Chicago Trust sold out of Biogen (BIIB) in Q3 2022, closing a stake of 2,740 shares — an estimated $559K sold.

Chicago Trust first reported a position in BIIB in Q4 2017 and held it in 19 quarters. The position peaked at $2.6M in Q2 2021. 986 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.

  • Chicago Trust reported no remaining Biogen position as of Q3 2022 after selling out during the quarter.
  • Chicago Trust sold 2,740 Biogen shares in Q3 2022, an estimated $559K.
  • Chicago Trust first reported a position in Biogen in Q4 2017 and held it in 19 quarters.
  • Chicago Trust's Biogen position peaked at $2.6M in Q2 2021.
  • 986 funds tracked by Wall St. Rank held Biogen as of Q3 2022.

Based on Chicago Trust's 13F filing for Q3 2022, filed 13 Oct 2022.